Portal de Periódicos da CAPES

Interactions between Calcium Channel Blockers and Non‐Cardiovascular Drugs: Interactions with Anticancer Drugs

1988; Wiley; Volume: 63; Issue: 1 Linguagem: Inglês

10.1111/j.1600-0773.1988.tb00899.x

1600-0773

José M. Baeyens,

PARP inhibition in cancer therapy

Pharmacology & ToxicologyVolume 63, Issue 1 p. 1-7 Free Access Interactions between Calcium Channel Blockers and Non-Cardiovascular Drugs: Interactions with Anticancer Drugs José M. Baeyens, José M. Baeyens Department of Pharmacology, University of Granada Medical School, Avda. de Madrid s/n, 18012 Granada, SpainSearch for more papers by this author José M. Baeyens, José M. Baeyens Department of Pharmacology, University of Granada Medical School, Avda. de Madrid s/n, 18012 Granada, SpainSearch for more papers by this author First published: July 1988 https://doi.org/10.1111/j.1600-0773.1988.tb00899.xCitations: 9AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat References Baeyens, J. M. & E. Del Pozo: Interactions between calcium channel blockers and non-cardiovascular drugs: Interactions with drugs acting at the neuromuscular or the CNS level. Pharmacology & Toxicology 1988, 62, 59–63, MiniReview. 10.1111/j.1600-0773.1988.tb01846.x CASPubMedWeb of Science®Google Scholar Beck, W. T., M. C. Cirtain, A. T. Look & R. A. Ashmun: Reversal of vinca alkaloid resistance but not multiple drug resistance in human leukemic cells by verapamil. Cancer Res. 1986, 46, 778–784. CASPubMedWeb of Science®Google Scholar Benson, A. B., D. L. Trump, J. M. Koeller, M. I. Egorin, E. A. Olman, R. S. Witte, T. E. Davis & D. C. Tormey: Phase I study of vinblastine and verapamil given by concurrent i.v. infusion. Cancer Treat. Rep. 1985, 69, 795–799. PubMedWeb of Science®Google Scholar Brouwer, R. M., F. Follath & F. R. Bühler: Review of the cardiovascular adversity of the calcium antagonists-beta blocker combination: implications for antihypertensive therapy. J. Cardiovasc. Pharmacol. 1985, 7, Suppl. 4, S 38–S 44. 10.1097/00005344-198507004-00008 Web of Science®Google Scholar Cantwell, B., P. Buamah & A. L. Harris: Phase I and II study of oral verapamil (VRP) and intravenous vindesine (VDN). Brit. J. Cancer 1985, 52, 425. Web of Science®Google Scholar De Vito, J. M. & B. Friedman: Evaluation of the pharmacodynamic and pharmacokinetic interaction between calcium antagonists and digoxin. Pharmacotherapy 1986, 6, 73–82. 10.1002/j.1875-9114.1986.tb03456.x PubMedWeb of Science®Google Scholar Fetherson, C. A., S. Merry, S. B. Kaye & R. I. Freshney: Verapamil enhances the sensitivity to adriamycin and VP 16–213 of human lung cancer in vitro. Brit. J. Cancer 1985, 51, 598–599. Google Scholar Fine, R. L., S. Koizumi, G. A. Curt & B. A. Chabner: Verapamil (VP) does not enhance anticancer drug toxicity for human marrow myeloid-macrophage colony forming units (CFU-GM). Proc. Am. Soc. Clin. Oncol. 1984, 2, 40. Google Scholar Friche, E., T. Skovsgaard & N. I. Nissen: Effects of verapamil on daunorubicin accumulation in Ehrlich ascites tumor cells. Cancer Chemother. Pharmacol. 1987, 19, 35–39. 10.1007/BF00296252 CASPubMedWeb of Science®Google Scholar Godfraind, T., R. Miller & M. Wibo: Calcium antagonism and calcium entry blockers. Pharmacol. Rev. 1986, 38, 321–417. CASPubMedWeb of Science®Google Scholar Hedner, T.: Calcium channel blockers: spectrum of side effects and drug interactions. Acta pharmacol. et toxicol 1986, 58, Suppl. II, 119–130. 10.1111/j.1600-0773.1986.tb02527.x CASPubMedWeb of Science®Google Scholar Hindenburg, A. A., M. A. Baker, E. Gleyzer, V. J. Stewart, N. Case & R. N. Taub: Effect of verapamil and other agents on the distribution of anthracyclines and on reversal of drug resistance. Cancer Res. 1987, 47, 1421–1425. CASPubMedWeb of Science®Google Scholar Honda, T., K. Sampi & M. Hattori: Combination therapy of vinca alkaloids and nicardipine in patients with non-Hodgkin's lymphoma who became resistant to various chemotherapeutic agents and relapsed. Jap. J. Cancer Chemother. 1983, 10, 2330–2334. CASPubMedGoogle Scholar Ikeda, H., G. Nakano, K. Nagashima, K. Sakamoto, N. Harasawa, T. Kitamura, T. Nakamura & Y. Nagamachi: Verapamil enhancement of antitumor effect of cis-diaminedichloroplatinum (II) in nude mouse-grown human neuroblastoma. Cancer Res. 1987, 47, 231–234. CASPubMedWeb of Science®Google Scholar Ince, P., D. R. Appleton, K. J. Finney, J. P. Sunter & A. J. Watson: Verapamil increases the sensitivity of primary human colorectal carcinoma tissue to vincristine. Brit. J. Cancer 1986, 53, 137–139. 10.1038/bjc.1986.19 CASPubMedWeb of Science®Google Scholar Kaba, K., E. Tani, T. Morimura & T. Matsumoto: Potentiation of vincristine effects in human and murine gliomas by calcium channel blockers or calmodulin inhibitors. J. Neurosurg. 1985, 63, 905–911. 10.3171/jns.1985.63.6.0905 CASPubMedWeb of Science®Google Scholar Kessel, D.: Interactions among membrane transport systems: anthracyclines, calcium antagonists and anti-estrogens. Biochem. Pharmacol. 1986, 35, 2825–2826. 10.1016/0006-2952(86)90196-6 CASPubMedWeb of Science®Google Scholar Kessel, D. & C. Wilberding: Mode of action of calcium antagonists which alter anthracycline resistance. Biochem. Pharmacol. 1984, 33, 1157–1160. 10.1016/0006-2952(84)90533-1 CASPubMedWeb of Science®Google Scholar Kessel, D. & C. Wilberding: Anthracycline resistance in P388 murine leukemia and its circumvention by calcium antagonists. Cancer Res. 1985, 45, 1687–1691. CASPubMedWeb of Science®Google Scholar Klohs, W. D., R. W. Steimkampf, M. J. Havlick & R. C. Jackson: Resistance to anthrapyrazoles and anthracyclines in multidrug-resistant P388 murine leukemia cells: Reversal by calcium channel blockers and calmodulin antagonists. Cancer Res. 1986, 46, 4352–4356. CASPubMedWeb of Science®Google Scholar Marcum, J. M., J. R. de Dman, B. R. Brinkley & A. R. Means: Control of microtubule assembly-disassembly by calcium dependent regulator proteins. Proc. Natl. Acad. Sci. U.S.A. 1978, 75, 3771–3775. 10.1073/pnas.75.8.3771 CASPubMedWeb of Science®Google Scholar Merry, S., C. A. Fetherson, S. B. Kaye, R. I. Freshney & J. A. Plumb: Resistance of human glioma to adriamycin in vitro: The role of membrane transport and its circumvention with verapamil. Brit. J. Cancer 1986, 53, 129–135. 10.1038/bjc.1986.18 CASPubMedWeb of Science®Google Scholar Morrow, M., R. B. Wait, R. A. Rosenthal & R. L. Gamelli: Verapamil enhances antitumor activity without increasing myeloid toxicity. Surgery 1987, 101, 63–68. CASPubMedWeb of Science®Google Scholar Müllerleile, U., M. Garbrecht, P. Hanrath, B. A. Langenstein, K. Bieber, W. Bleifeld & D. K. Hossfeld: Possible prevention of adriamycin-related cardiomyopathy using verapamil. Klin. Woch. 1984, 62, 1032–1037. 10.1007/BF01711726 CASPubMedWeb of Science®Google Scholar Offerman, J. J. G., S. Meijer, D. Th. Sleijfer, N. H. Mulder, A. J. M. Donker, H. Shraffordt Koops & G. K. Van der Hem: The influence of verapamil on renal function in patients treated with cisplatin. Clin. Nephrol. 1985, 24, 249–255. CASPubMedWeb of Science®Google Scholar Onoda, J. M., J. R. Jacobs, J. D. Taylor, B. F. Sloane & K. V. Honn: Cisplatin and nifedipine: synergistic cytotoxicity against murine solid tumors and their metastases. Cancer Letts. 1986, 30, 181–188. 10.1016/0304-3835(86)90087-X CASPubMedWeb of Science®Google Scholar Ozols, R. F., A. M. Rogan, T. C. Hamilton, R. Klecker & R. C. Young: Verapamil (VP) plus adryamicin (ADR) in refractory ovarian cancer (OC): design of a clinical trial on basis of reversal of ADR resistance (R) in human OC cell lines. Proc. Am. Assoc. Cancer Res. 1984, 25, 300. Web of Science®Google Scholar Presant, C. A., P. Kennedy, C. Wiseman, K. Gata & M. Wyres: Verapamil (V) plus adryamicin (A): A phase I-II clinical study. Proc. Am. Soc. Clin. Oncol. 1984, 2, 32. Google Scholar Ramu, A., Z. Fuks, S. Gatt & D. Glaubiger: Reversal of acquired resistance to doxorubicin in P388 murine leukemia cells by per-hexiline maleate. Cancer Res. 1984a, 44, 144–148. CASPubMedWeb of Science®Google Scholar Ramu, A., R. Spanier, H. Rahamimoff & Z. Fuks: Restoration of doxorubicin responsiveness in doxorubicin-resistant P388 murine leukemia cells. Brit. J. Cancer 1984b, 50, 501–507. 10.1038/bjc.1984.207 CASPubMedWeb of Science®Google Scholar Ramu, A. & H. Weentraub: Differences in lipid composition of doxorubicin-sensitive and -resistant P388 cells. Cancer Treat. Rep. 1984, 68, 637–641. CASPubMedWeb of Science®Google Scholar Robinson, B. A., R. D. Clutterbuck, J. L. Millar & T. J. McElwain: Verapamil potentiation of melphalan cytotoxicity and cellular uptake in murine fibrosarcoma and bone marrow. Brit. J. Cancer 1985, 52, 813–822. 10.1038/bjc.1985.264 CASPubMedWeb of Science®Google Scholar Rogan, A. M., T. C. Hamilton, R. C. Young, R. W. Klecker & R. F. Ozols: Reversal of adriamycin resistance by verapamil in human ovarian cancer. Science 1984, 224, 994–996. 10.1126/science.6372095 CASPubMedWeb of Science®Google Scholar Simmonds, A. P., P. Moyes, A. Nicol, K. G. Davidson & A. Faichney: Enhancement of cytotoxicity of vindesine and cis-platinum for human lung tumours by the use of verapamil in vitro. Brit. J. Cancer 1986, 54, 1015–1018. 10.1038/bjc.1986.274 CASPubMedWeb of Science®Google Scholar Simpsom, W. G., M. T. Tseng, K. C. Anderson & J. I. Harty: Verapamil enhancement of chemotherapeutic efficacy in human bladder cancer cells. J. Urol. 1984, 132, 574–576. PubMedWeb of Science®Google Scholar Skovsgaard, T., K. Danø & N. I. Nissen: Chemosensitizers counteracting acquired resistance to anthracyclines and vinca alkaloids in vivo. A new treatment principle. Cancer Treat. Rev. 1984, 11, Suppl. A, 63–72. 10.1016/0305-7372(84)90044-6 CASPubMedWeb of Science®Google Scholar Slater, L. M., S. L. Murray, M. W. Wetzel, P. Sweet & M. Stupecky: Verapamil potentiation of VP-16–213 in acute lymphatic leukemia and reversal of pleiotropic drug resistance. Cancer Chemother. Pharmacol. 1986, 16, 50–54. 10.1007/BF00255285 CASPubMedWeb of Science®Google Scholar Slater, L. M., S. L. Murray, M. W. Wetzel, R. M. Wisdom & E. M. Duvall: Verapamil restoration of daunorubicin responsiveness in daunorubicin-resistant Ehrlich ascites carcinoma. J. Clin. Invest. 1982, 70, 1131–1134. 10.1172/JCI110702 CASPubMedWeb of Science®Google Scholar Spedding, M.: Activators and inactivators of calcium channels: new perspectives. J. Pharmacol. 1985, 16, 319–343. CASPubMedWeb of Science®Google Scholar Tsuruo, T.: Reversal of acquired resistance to vinca alkaloids and anthracycline antibiotics. Cancer Treat. Rep. 1983, 67, 889–894. CASPubMedWeb of Science®Google Scholar Tsuruo, T., H. Iida, H. Kabawata, S. Tuskagoshi & Y. Sakurai: High calcium content of pleiotropic drug-resistant P388 and K562 leukemic cells and Chinese hamster ovary cells. Cancer Res. 1984, 44, 144–148. PubMedWeb of Science®Google Scholar Tsuruo, T., H. Iida, K. Nagamuna, S. Tsukagoshi & Y. Sakurai: Promotion by verapamil of vincristine responsiveness in tumor cell lines inherently resistant to the drug. Cancer Res. 1983a, 43, 808–813. CASPubMedWeb of Science®Google Scholar Tsuruo, T., H. Iida, M. Nojiri, S. Tsukagoshi & Y. Sakurai: Circumvention of vincristine and adriamycin resistance in vitro and in vivo by calcium influx blockers. Cancer Res. 1983b, 43, 2905–2910. CASPubMedWeb of Science®Google Scholar Tsuruo, T., H. Iida, S. Tsukagoshi & Y. Sakurai: Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil. Cancer Res. 1981, 41, 1967–1972. CASPubMedWeb of Science®Google Scholar Tsuruo, T., H. Iida, S. Tsukagoshi & Y. Sakurai: Increased accumulation of vincristine and adriamycin in drug-resistant P388 tumor cells following incubation with calcium antagonists and calmodulin inhibitors. Cancer Res. 1982a, 42, 4730–4733. CASPubMedWeb of Science®Google Scholar Tsuruo, T., H. Iida, S. Tsukagoshi & Y. Sakurai: Potentiation of vincristine and adriamycin effects in human hemopoietic tumor cell lines by calcium antagonists and calmodulin inhibitors. Cancer Res. 1983c, 43, 2267–2272. CASPubMedWeb of Science®Google Scholar Tsuruo, T., H. Iida, M. Yamashiro, S. Tsukagoshi & Y. Sakurai: Enhancement of vincristine- and adriamycin-induced cytotoxicity by verapamil in P388 leukemia and its sublines resistant to vincristine and adriamycin. Biochem. Pharmacol. 1982b, 31, 3138–3140. 10.1016/0006-2952(82)90097-1 CASPubMedWeb of Science®Google Scholar Tsuruo, T., H. Kawabata, N. Nagumo, H. Iida, Y. Kitatani, S. Tsukagoshi & Y. Sakurai: Potentiation of antitumor agents by calcium channel blockers with special reference to cross-resistance patterns. Cancer Chemother. Pharmacol. 1985, 15, 16–19. 10.1007/BF00257287 CASPubMedWeb of Science®Google Scholar Vassilev, P. M., M. P. Kanazirska, L. J. Charamella, N. V. Dimitrov & H. T. Tien: Changes in calcium channel activity in membranes from cis-diammine-dichloroplatinum (II)-resistant and - sensitive L1210 cells. Cancer Res. 1987, 47, 519–522. CASPubMedWeb of Science®Google Scholar Yalowich, J. C. & W. E. Ross: Potentiation of etoposide-induced DNA damage by calcium antagonists in L1210 cells in vitro. Cancer Res. 1984, 44, 3360–3365. CASPubMedWeb of Science®Google Scholar Yalowich, J. C. & W. E. Ross: Verapamil-induced augmentation of etoposide accumulation in L1210 cells in vitro. Cancer Res. 1985, 45, 1651–1656. CASPubMedWeb of Science®Google Scholar Yalowich, J. C., J. R. Zucali, M. A. Gross & W. E. Ross: Effects of verapamil on etoposide, vincristine, and adriamycin activity in normal human bone marrow granulocyte-macrophage progenitors and in human K562 leukemia cells in vitro. Cancer Res. 1985, 45, 4921–4924. CASPubMedWeb of Science®Google Scholar Yanowich, S. & L. Preston: Effects of verapamil on daunomycin cellular retention and cytotoxicity in P388 leukemic cells. Cancer Res. 1984, 44, 1743–1747. PubMedWeb of Science®Google Scholar Citing Literature Volume63, Issue1July 1988Pages 1-7 ReferencesRelatedInformation